Cell Impact Q2 2026: Progress continues despite prolonged lead times
Idag, 08:03
Cell Impact Q2 2026: Progress continues despite prolonged lead times
During the second quarter, Cell Impact continued to make progress on customer projects, strengthen customer relationships and prepare the company’s operations for the upcoming volume production. In parallel, Cell Impact was impacted by long lead times and delayed investment decisions, which continued to dominate the hydrogen market.
During the first half of the year, Cell Impact worked on a major transaction involving the sale of a large number of machines. The transaction was in the final stage of negotiations but was temporarily put on hold due to developments in the customer’s project.
“The delay was one important reason for the financing measures we implemented during the quarter. We decided to conduct a rights issue of approximately SEK 53.6 million, before issue costs and repayment of bridge loans,“ said Daniel Vallin, CEO of Cell Impact.
Cell Impact’s ambition remains unchanged: to create the necessary conditions to secure and deliver the major orders the company believes lie ahead, and to continue strengthening the position as a leading supplier of cost-efficient flow plates and related production solutions.
“By building up our expertise, processes and capacity, we have created a platform that is ready to handle increased volumes as customers take the next step in their projects. We are continuing to move forward, step by step, focusing on customer relationships, cost control and business activities that generate sales, cash flow and long-term value,” Daniel Vallin concluded.
Financial summary:
- Net sales totaled SEK 1.4 million (2.1).
- The operating loss (EBIT) amounted to SEK –17.4 million (–20.0).
- The Group’s loss after financial items was SEK –17.7 million (–21.2).
- Earnings per share attributable to the Parent Company’s shareholders before and after dilution totaled SEK –0.04 (–0.03).
- Debt/equity ratio was 75 percent (78) on the balance sheet date.
- Cash flows from operating activities amounted to SEK –2.4 million (–11.9).
- On the balance sheet date, the Group’s cash and cash equivalents totaled SEK 0.4 million (1.0). As of August 4, 2026, the cash balance amounted to SEK 2.9 million.
This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.
About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power. The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company’s Certified Advisor (CA).
For more information, please contact:
Daniel Vallin
CEO and IR contact, Cell Impact AB
+46 730-68 66 20 or daniel.vallin@cellimpact.com
Malin Lundberg
CFO, Cell Impact AB
+46 70-390 79 59 or malin.lundberg@cellimpact.com
Ämnen i artikeln
Cell Impact Q2 2026: Progress continues despite prolonged lead times
Idag, 08:03
Cell Impact Q2 2026: Progress continues despite prolonged lead times
During the second quarter, Cell Impact continued to make progress on customer projects, strengthen customer relationships and prepare the company’s operations for the upcoming volume production. In parallel, Cell Impact was impacted by long lead times and delayed investment decisions, which continued to dominate the hydrogen market.
During the first half of the year, Cell Impact worked on a major transaction involving the sale of a large number of machines. The transaction was in the final stage of negotiations but was temporarily put on hold due to developments in the customer’s project.
“The delay was one important reason for the financing measures we implemented during the quarter. We decided to conduct a rights issue of approximately SEK 53.6 million, before issue costs and repayment of bridge loans,“ said Daniel Vallin, CEO of Cell Impact.
Cell Impact’s ambition remains unchanged: to create the necessary conditions to secure and deliver the major orders the company believes lie ahead, and to continue strengthening the position as a leading supplier of cost-efficient flow plates and related production solutions.
“By building up our expertise, processes and capacity, we have created a platform that is ready to handle increased volumes as customers take the next step in their projects. We are continuing to move forward, step by step, focusing on customer relationships, cost control and business activities that generate sales, cash flow and long-term value,” Daniel Vallin concluded.
Financial summary:
- Net sales totaled SEK 1.4 million (2.1).
- The operating loss (EBIT) amounted to SEK –17.4 million (–20.0).
- The Group’s loss after financial items was SEK –17.7 million (–21.2).
- Earnings per share attributable to the Parent Company’s shareholders before and after dilution totaled SEK –0.04 (–0.03).
- Debt/equity ratio was 75 percent (78) on the balance sheet date.
- Cash flows from operating activities amounted to SEK –2.4 million (–11.9).
- On the balance sheet date, the Group’s cash and cash equivalents totaled SEK 0.4 million (1.0). As of August 4, 2026, the cash balance amounted to SEK 2.9 million.
This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.
About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power. The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company’s Certified Advisor (CA).
For more information, please contact:
Daniel Vallin
CEO and IR contact, Cell Impact AB
+46 730-68 66 20 or daniel.vallin@cellimpact.com
Malin Lundberg
CFO, Cell Impact AB
+46 70-390 79 59 or malin.lundberg@cellimpact.com
Ämnen i artikeln
Aktieanalys
Rapporter
AstraZeneca
Aktieanalys
Rapporter
AstraZeneca
Marknadsöversikt
1 DAG %
Senast
1 mån
